RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Bruce Shiramizu to Child, Preschool

This is a "connection" page, showing publications Bruce Shiramizu has written about Child, Preschool.
Connection Strength

0.358
  1. Shiramizu B, Mussolin L, Woessmann W, Klapper W. Paediatric non-Hodgkin lymphoma - perspectives in translational biology. Br J Haematol. 2016 05; 173(4):617-24.
    View in: PubMed
    Score: 0.100
  2. Shiramizu B, Goldman S, Smith L, Agsalda-Garcia M, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Barth MJ, Mussolin L, Cairo MS. Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report. Br J Haematol. 2015 Aug; 170(3):367-71.
    View in: PubMed
    Score: 0.093
  3. Shiramizu B, Perkins SL, Bergeron S, Lones M, Kelly K, Weiner M, Cairo MS. Assessing immunoglobulin heavy chain rearrangements in pediatric CD20-positive and CD20-negative classic Hodgkin's disease. Clin Lymphoma. 2004 Dec; 5(3):184-9.
    View in: PubMed
    Score: 0.045
  4. Sabesan V, Cairo MS, Lones MA, Perkins SL, Morris E, Sposto R, Van De Ven C, Shiramizu B. Assessment of minimal residual disease in childhood non-hodgkin lymphoma by polymerase chain reaction using patient-specific primers. J Pediatr Hematol Oncol. 2003 Feb; 25(2):109-13.
    View in: PubMed
    Score: 0.040
  5. Goldman S, Barth M, Shiramizu B, Shi Q, Hochberg J, Klejmont L, Harrison L, Basso J, Chu Y, Islam H, Gerard P, Agsalda-Garcia M, Shieh T, Oesterheld J, Heym K, Kirov I, Drachtman R, Harker-Murray P, Perkins S, Miles RR, Cairo M. A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma. Leukemia. 2021 10; 35(10):2994-2997.
    View in: PubMed
    Score: 0.035
  6. Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Geyer MB, Gross TG, Weinstein H, Bergeron S, Shiramizu B, Sanger W, Barth M, Zhi J, Cairo MS. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia. 2013 Apr; 27(5):1174-7.
    View in: PubMed
    Score: 0.019
  7. Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, Shiramizu B, Wiley J, Woods D, Barnich M, Gross TG. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Feb; 52(2):177-81.
    View in: PubMed
    Score: 0.015
  8. Yu Q, Shiramizu B, Nerurkar VR, Hu N, Shikuma CM, Melish ME, Cascio K, Imrie A, Lu Y, Yanagihara R. TT virus: preferential distribution in CD19(+) peripheral blood mononuclear cells and lack of viral integration. J Med Virol. 2002 Feb; 66(2):276-84.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support